- Home
- FNLC vs ALLO Comparison
FNLC vs ALLO Comparison
Compare FNLC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | ALLO |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.9M | 452.6M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FNLC | ALLO |
|---|---|---|
| Price | $36.64 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 33.4K | ★ 5.3M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | 26.34 | ★ 34.09 |
| EPS | ★ 1.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $255.46 |
| P/E Ratio | $21.84 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.39 | $1.04 |
| 52 Week High | $36.30 | $4.46 |
Technical Indicators
Market Signals| Indicator | FNLC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 70.93 | 25.84 |
| Support Level | $34.28 | $1.22 |
| Resistance Level | N/A | $2.22 |
| Average True Range (ATR) | 0.94 | 0.08 |
| MACD | 0.35 | 0.00 |
| Stochastic Oscillator | 100.00 | 25.00 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).